Skip to content

The Study of Individualized Optimal Muscle Relaxant Dosing Regimen for Urology Surgical Patients based on Population Pharmacokinetic/pharmacodynamic Models

The Study of Individualized Optimal Muscle Relaxant Dosing Regimen for Urology Surgical Patients based on Population Pharmacokinetic/pharmacodynamic Models

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116191
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urology disease that require surgery

Interventions

data collection for model establishment (general anesthesia with muscle relaxants):None
model validation (general anesthesia, and using muscle relaxants according to modeling and stimulation):None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.urology surgical patients, age 18 ~ 85; 2.surgery duration >= 20 min; 3.general anesthesia, using nondepolarizing neuromuscular blocking agents (muscle relaxants); 4.capable of handgrip strength test, feasible for intra-operative TOF (train of four) monitoring; 5.Capable of understanding the study protocol and procedures, willingness to comply with all study requirements, and voluntary provision of written informed consent;

Exclusion criteria

Exclusion criteria: 1.intra-operative massive hemorrhage, severe shock, or situations that obviously disturb drug effects and elimination of drugs; 2.intra-operative blood transfusion; 3.absence of TOF monitoring data; 4.change the type of anesthesia into non-general anesthesia, or general anesthesia without muscular relaxants; 5.failure of blood sample collection resulting in multiple plasma drug concentration absence/missing; 6.other situations considered unsuitable for participation by researchers;

Design outcomes

Primary

MeasureTime frame
pharmacodynamic effects;plasma concentration of muscle relaxants;

Secondary

MeasureTime frame
hand grip strength;muscle relaxants related adverse events;

Countries

China

Contacts

Public ContactYinQinqin

West China Hospital of Sichuan University

yinqinqin@wchscu.cn+86 28 8542 3913

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026